292 related articles for article (PubMed ID: 20433884)
21. Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo.
Wu YQ; Song Z; Zhou CH; Xing SH; Pei DS; Zheng JN
Oncol Rep; 2010 Nov; 24(5):1179-84. PubMed ID: 20878108
[TBL] [Abstract][Full Text] [Related]
22. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
23. Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue.
Billard E; Hébert TE; Chatenet D
J Med Chem; 2018 Oct; 61(19):8707-8716. PubMed ID: 30183282
[TBL] [Abstract][Full Text] [Related]
24. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
25. Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis.
Khan K; Albanese I; Yu B; Shalal Y; Al-Kindi H; Alaws H; Tardif JC; Gourgas O; Cerutti M; Schwertani A
J Thorac Cardiovasc Surg; 2021 Jan; 161(1):e1-e15. PubMed ID: 31679703
[TBL] [Abstract][Full Text] [Related]
26. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
27. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.
Sugo T; Murakami Y; Shimomura Y; Harada M; Abe M; Ishibashi Y; Kitada C; Miyajima N; Suzuki N; Mori M; Fujino M
Biochem Biophys Res Commun; 2003 Oct; 310(3):860-8. PubMed ID: 14550283
[TBL] [Abstract][Full Text] [Related]
28. Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain.
Mori M; Fujino M
Peptides; 2004 Oct; 25(10):1815-8. PubMed ID: 15476951
[TBL] [Abstract][Full Text] [Related]
29. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
[TBL] [Abstract][Full Text] [Related]
30. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues.
Morimoto R; Satoh F; Murakami O; Totsune K; Arai Y; Suzuki T; Sasano H; Ito S; Takahashi K
Peptides; 2008 May; 29(5):873-80. PubMed ID: 17686550
[TBL] [Abstract][Full Text] [Related]
31. Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.
Chatenet D; Nguyen QT; Létourneau M; Dupuis J; Fournier A
Biochem Pharmacol; 2012 Mar; 83(5):608-15. PubMed ID: 22197588
[TBL] [Abstract][Full Text] [Related]
32. Towards Targeting the Urotensinergic System: Overview and Challenges.
Nassour H; Iddir M; Chatenet D
Trends Pharmacol Sci; 2019 Oct; 40(10):725-734. PubMed ID: 31500846
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.
Langham RG; Kelly DJ; Gow RM; Zhang Y; Dowling JK; Thomson NM; Gilbert RE
Am J Kidney Dis; 2004 Nov; 44(5):826-31. PubMed ID: 15492948
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
[TBL] [Abstract][Full Text] [Related]
35. Potent cardiovascular effects of homologous urotensin II (UII)-related peptide and UII in unanesthetized eels after peripheral and central injections.
Nobata S; Donald JA; Balment RJ; Takei Y
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R437-46. PubMed ID: 21123764
[TBL] [Abstract][Full Text] [Related]
36. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide.
Boivin S; Guilhaudis L; Milazzo I; Oulyadi H; Davoust D; Fournier A
Biochemistry; 2006 May; 45(19):5993-6002. PubMed ID: 16681371
[TBL] [Abstract][Full Text] [Related]
37. Urotensin II, from fish to human.
Vaudry H; Do Rego JC; Le Mevel JC; Chatenet D; Tostivint H; Fournier A; Tonon MC; Pelletier G; Conlon JM; Leprince J
Ann N Y Acad Sci; 2010 Jul; 1200():53-66. PubMed ID: 20633133
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts.
Quan FB; Bougerol M; Rigour F; Kenigfest NB; Tostivint H
Gen Comp Endocrinol; 2012 May; 177(1):205-12. PubMed ID: 22433941
[TBL] [Abstract][Full Text] [Related]
39. Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists.
Billard E; Hébert TE; Chatenet D
Biochem Pharmacol; 2023 May; 211():115485. PubMed ID: 36889446
[TBL] [Abstract][Full Text] [Related]
40. An investigation into the origin of the biased agonism associated with the urotensin II receptor activation.
Brancaccio D; Merlino F; Limatola A; Yousif AM; Gomez-Monterrey I; Campiglia P; Novellino E; Grieco P; Carotenuto A
J Pept Sci; 2015 May; 21(5):392-9. PubMed ID: 25694247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
